Table 3.
The distribution of three newly defined immunophenotypes in all enrolled cohorts
| Dataset | No. of patients | Immunophenotype distribution, n (%) |
||
|---|---|---|---|---|
| Immune activated | Immune exhausted | Non-immune | ||
| TCGA-BLCA | 408 | 45 (11.03) | 110 (26.96) | 253 (62.01) |
| E-MTAB-4321 | 476 | 74 (15.55) | 111 (23.32) | 291 (61.13) |
| IMvigor210 | 348 | 85 (24.43) | 142 (40.8) | 121 (34.77) |
| GSE32894 | 308 | 42 (13.64) | 79 (25.65) | 187 (60.71) |
| GSE83586 | 307 | 63 (20.52) | 93 (30.29) | 151 (49.19) |
| GSE87304 | 305 | 59 (19.34) | 85 (27.87) | 161 (52.79) |
| GSE128702 | 256 | 72 (28.13) | 88 (34.38) | 96 (37.50) |
| GSE13507 | 164 | 23 (14.02) | 36 (21.95) | 105 (64.02) |
| GSE129871 | 158 | 26 (16.46) | 27 (17.09) | 105 (66.46) |
| GSE120736 | 145 | 21 (14.48) | 35 (24.14) | 89 (61.38) |
| GSE39016 | 141 | 16 (11.35) | 31 (21.99) | 94 (66.67) |
| GSE128701 | 136 | 42 (30.88) | 34 (25.00) | 60 (44.12) |
| GSE124035 | 133 | 32 (24.06) | 54 (40.6) | 47 (35.34) |
| GSE86411 | 132 | 22 (16.67) | 36 (27.27) | 74 (56.06) |
| GSE48276 | 116 | 24 (20.69) | 29 (25.00) | 63 (54.31) |
| GSE128192 | 112 | 26 (23.21) | 36 (32.14) | 50 (44.64) |
| GSE31684 | 93 | 14 (15.05) | 34 (36.56) | 45 (48.39) |
| GSE134292 | 80 | 13 (16.25) | 16 (20.00) | 51 (63.75) |
| GSE93527 | 79 | 13 (16.46) | 15 (18.99) | 51 (64.56) |
| E-MTAB-1803 | 70 | 13 (18.57) | 19 (27.14) | 38 (54.29) |
| GSE69795 | 61 | 9 (14.75) | 19 (31.15) | 33 (54.10) |